MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
2.937
+0.017
+0.58%
Opening 11:37 04/20 EDT
OPEN
2.880
PREV CLOSE
2.920
HIGH
2.940
LOW
2.880
VOLUME
4.83K
TURNOVER
--
52 WEEK HIGH
20.59
52 WEEK LOW
2.430
MARKET CAP
12.45M
P/E (TTM)
-0.3515
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLRB last week (0413-0417)?
Weekly Report · 6h ago
Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
TipRanks · 4d ago
Cellectar Biosciences enrolls first patient in CLR 121125 trial
TipRanks · 6d ago
Cellectar Biosciences Enrolls First Participant In Its Phase 1b Study Of CLR 121125 To Treat Triple Negative Breast Cancer
Benzinga · 6d ago
Cellectar enrolls first patient in Phase 1b CLR 125 trial for TNBC
PUBT · 6d ago
CELLECTAR ENROLLS FIRST PATIENT IN CLR 125 AUGER-EMITTING RADIOCONJUGATE PHASE 1B CLINICAL TRIAL TARGETING REFRACTORY TRIPLE NEGATIVE BREAST CANCER (TNBC)
Reuters · 6d ago
Weekly Report: what happened at CLRB last week (0406-0410)?
Weekly Report · 04/13 10:22
Weekly Report: what happened at CLRB last week (0330-0403)?
Weekly Report · 04/06 10:23
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.